Thyrocare Technologies Approves In-Principle Evaluation of NHL Radiology Business Demerger

Thyrocare Technologies Approves In-Principle Evaluation of NHL Radiology Business Demerger​

Thyrocare Technologies Ltd has announced that its Board of Directors has given in-principle approval for evaluating a proposed restructuring involving a portion of its subsidiary’s business. The focus of the potential transaction is the demerger of Nueclear Healthcare Limited (NHL) radiology operations outside of the existing group structure.

Nueclear Healthcare Limited, a wholly owned subsidiary of Thyrocare Technologies Ltd, operates in the specialized field of advanced cancer diagnostics and nuclear medicine. NHL runs PET-CT and CT imaging centers and provides comprehensive nuclear medicine diagnostic services. The company also manufactures radiopharmaceuticals using its medical cyclotron facilities, supporting the diagnosis, staging, and monitoring of complex diseases and cancers.

The Board meeting held by Thyrocare Technologies Ltd reviewed and approved the initial evaluation of this proposed restructuring. The demerger plan allows NHL’s radiology business undertaking to be transferred outside the group through various methods, which may include a scheme of arrangement, slump sale, business transfer, or another suitable structure that needs subsequent assessment.

The company confirmed that the Proposed Restructuring is currently at the in-principle evaluation stage. Detailed terms and conditions of the transaction will be presented for review by the Board of Directors of NHL once sufficient progress has been made. This process remains subject to requisite statutory and regulatory approvals.

THYROCARE Stock Price Movement​

Shares of Thyrocare Technologies Limited today shed 2.41% in post-market trading, settling at ₹545.25. The stock traded during the session between a low of ₹541 and a high of ₹558.6, with a total volume of 312,670 shares transacted.